Company intelligence / Profile preview

PDX Pharmaceuticals

Portland, Oregon, United Statespdxpharm.com ↗

Ownership: Private
Development stage: Other

Overview

PDX Pharmaceuticals is conducting IND-enabling studies for its lead drug candidates ARAC™ and AIRISE™, both funded by the National Cancer Institute. The company is preparing to initiate clinical trials by 2025. Their proprietary nanoparticle platform enables targeted delivery of multiple therapeutic agents to solid tumors and has shown promise in preclinical models for overcoming resistance to current therapies and generating robust antitumor immune responses.

Therapeutic areas: Oncology
Modalities: NanoparticleSmall moleculeAntibodyRNA therapy (siRNA)VaccineImmunotherapy (combination)
Industry: Biotech

Partnerships

Knight Cancer Institute at Oregon Health & Science University [OHSU]Supported by NIH agencies including NCI, NCATS, NIDDK, NIGMS, NIEHS, NIAIDONAMIPacific Northwest National Laboratory [PNNL]Multiple foundations supporting research funding

Beyond the preview

Go deeper on PDX Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PDX Pharmaceuticals.

Explore the full profile